康宁杰瑞制药-B(09966.HK)上半年研发开支大幅增至1.34亿元
格隆汇8月28日丨康宁杰瑞制药-B(09966.HK)公布,截至2020年6月30日止6个月,集团录得其他收入为4430万元人民币(单位下同),截至2019年6月30日止6个月为1100万元;录得亏损及全面开支总额为1.03亿元,截至2019年6月30日止6个月为5880万元。
截至2020年6月30日止6个月,研发开支较截至2019年6月30日止6个月的5580万元增加7790万元至1.34亿元,主要原因为(i)正在进行的临床试验数量增加;(ii)临床研究规模扩大;(iii)推进候选药物临床试验;(iv)因研发员工增加及因向员工授出期权导致薪酬增加,从而导致员工成本增加;及(v)临床试验增加导致用药需求增加,进而导致生产成本增加。
迄今为止,集团计划于2020年开始在中国建立集团自身的商业化团队,将重心初步放在后期候选药物及建立一支致力于医疗事宜及政府事宜的团队,为将来于2022年推出KN046作准备。
此外,集团计划继续扩大集团的团队以积极寻求来自第三方付款方及政府报销项目的保险及报销机会,从而支持KN046的持续商业运作及即将推出的KN026。集团期望将集团的团队覆盖到中国的主要省市,尤其是经济相对发达及可支配收入水平相对较高的省市。集团打算继续扩大集团的团队以期推出更多的产品及获批更多的适应症。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.